The influence of β adrenobloker Nebivolol on lipid spectrum in patients with metabolic syndrome A study of a group of 63 patients with metabolic syndrome, with average age of 49±0,6 years, was carried out. The control group included 56 patients with the same age as the study group with arterial hypertension, without metabolic syndrome. The criterion of inclusion in the study group was arterial hypertension I-II degree associated with obesity. The administration of the long term treatment with Nebivolol 5 mg in patients with arterial hypertension and obesity hasn’t negatively influenced the lipid spectrum of these patients. But in patients with metabolic syndrome it improves the lipid spectrum state with significant reducion of triglyceride, total cholesterol and LDL-cholesterol values.

A fost efectuat studiul unui lot de 63 pacienţi cu sindrom metabolic cu vîrsta medie 49±0,6 ani, lotul de control fiind constituit din 56 pacienţi de aceeaşi vîrstă cu hipertensiune arterială fără sindrom metabolic. Criteriu de includere în grupul de cercetare a fost hipertensiunea arterială de gradul I-II în asociere cu obezitatea. Administrarea tratamentului de durată cu Nebivolol 5mg pacienţilor hipertensivi obezi nu a influienţat negativ starea spectrului lipidic la pacienţii cu hipertensiune arterială şi obezitate. Dar la pacienţii cu sindrom metabolic ameliorează starea spectrului lipidic prin reducerea semnificativă a valorilor trigliceridelor, colesterolului total şi LDL-colesterolului.